Wellbeing Digital Sciences Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program
The Treatment was Successfully Performed in Ontario as Part of the Company’s Previously Announced Collaboration with Victoria Wellness and iHealthOX
Vancouver, British Columbia, February 15, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce the successful facilitation of its first intravenous (“IV”) ketamine treatment to a patient at the Victoria Wellness Mental Health Residential and Addition Treatment Centre (“VW” or the “Centre”) in Ontario through its collaboration with iHealthOX. VW is one of the first in-patient facilities to offer ketamine-assisted therapy in Canada. Wellbeing management expects the collaboration between VW, iHealthOX and itself to experience an increase in the number of patients treated via IV ketamine infusions in the near future.
The Centre, located at 5316 Rice Lake Scenic Drive in Gores Landing, Ontario, is a residential rehabilitation facility and mental health clinic focused on treating anxiety, depression, and post-traumatic stress disorder (“PTSD”) by offering personalized therapy treatment programs. The Company and VW have launched a first-class, best practice-based, six-week inpatient Ketamine Integrated Therapy Experience (“KITE”) program. The first three weeks of the KITE program are structured to offer clients a unique opportunity to benefit from fast-acting and medically supervised IV ketamine administration. This process is expected to help combat long-standing and prescription-resistant mental health conditions such as depression and PTSD.
The Company’s previous announced arrangement with iHealthOX helped to make this first IV ketamine treatment possible. iHealthOX was created to provide patients with a customized digital tool specifically for mental health. Patients have access to live coaching sessions, options for one-on-one therapy, evidence based educational material, and 24/7 emergency support. The iHealthOX platform will be available to patients in both desktop and mobile versions, thereby extending the Company’s services beyond its clinic locations.
“The success of our first IV ketamine treatment in Canada in collaboration with VW and iHealthOX and Wellbeing is encouraged that ketamine-based treatments for mental health are becoming more commonplace. The Company has always wanted to make a positive and significant impact on mental health and this brings us one step closer,” said Adam Deffett, Interim CEO of Wellbeing. “Achievements like this,
exemplify why Wellbeing continues to work hard to make a difference in the mental health realm,” added Mr. Deffett.
ABOUT WELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine assisted therapies and other types of treatment to patients as well as through a contract research organization that offer clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.
On behalf of:
WELLBEING DIGITAL SCIENCES INC.
“Adam Deffett”
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co
Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward
looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.